TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial.

MLA

Constantine, Ginger D., et al. “TX-001HR Is Associated with a Clinically Meaningful Effect on Severity of Moderate to Severe Vasomotor Symptoms in the REPLENISH Trial.” Menopause (New York, N.Y.), vol. 27, no. 11, Nov. 2020, pp. 1236–41. EBSCOhost, https://doi.org/10.1097/GME.0000000000001602.

APA

Constantine, G. D., Simon, J. A., Kaunitz, A. M., Pickar, J. H., Revicki, D. A., Graham, S., Bernick, B., & Mirkin, S. (2020). TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial. Menopause (New York, N.Y.), 27(11), 1236–1241. https://doi.org/10.1097/GME.0000000000001602

Chicago

Constantine, Ginger D, James A Simon, Andrew M Kaunitz, James H Pickar, Dennis A Revicki, Shelli Graham, Brian Bernick, and Sebastian Mirkin. 2020. “TX-001HR Is Associated with a Clinically Meaningful Effect on Severity of Moderate to Severe Vasomotor Symptoms in the REPLENISH Trial.” Menopause (New York, N.Y.) 27 (11): 1236–41. doi:10.1097/GME.0000000000001602.